Charles Owens
Research Subjects
Research Interests
Charles Owens has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Dan Theodorescu
University of Arizona Comprehensive Cancer Center, Tucson, AZ, USA
20 shared publications Ana Chauca-Diaz
19 shared publicationsColin Sempeck
19 shared publications- Debashis Ghosh
Department of Biostatistics & Informatics, University of Colorado-Anschutz Medical Campus , Aurora, Colorado
19 shared publications Donna E. Hansel
19 shared publications- Joseph L. Sottnik
Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
19 shared publications
Latest Publications
- Open Access
- 24 October 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (1) , 19-29
Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma
Rhabdomyosarcoma (RMS), a malignancy of impaired myogenic differentiation, is the most common soft tissue pediatric cancer. PAX3-FOXO1 oncofusions drive the majority of the clinically more aggressive fusion-positive rhabdomyosarcoma (FP-RMS). Recent studies have established an epigenetic basis for PAX3-FOXO1-driven oncogenic processes. However, details of PAX3-FOXO1 epigenetic mechanisms, including interactions with, and dependence on, other chromatin and transcription factors, are incompletely understood. We previously identified a novel disease-promoting epigenetic axis in RMS, involving the histone demethylase KDM3A and the ETS1 transcription factor, and demonstrated that this epigenetic axis interfaces with PAX3-FOXO1 both phenotypically and transcriptomically, including co-regulation of biological processes and genes important to FP-RMS progression. In this study, we demonstrate that KDM3A and ETS1 colocalize with PAX3-FOXO1 to enhancers of important disease-promoting genes in FP-RMS, including FGF8, IL4R, and MEST, as well as PODXL, which we define herein as a new FP-RMS-promoting gene. We show that ETS1, which is induced by both PAX3-FOXO1 and KDM3A, exists in complex with PAX3-FOXO1, and augments PAX3-FOXO1 chromatin occupancy. We further show that the PAX3-FOXO1/ETS1 complex can be disrupted by the clinically relevant small molecule inhibitor YK-4-279. YK-4-279 displaces PAX3-FOXO1 from chromatin and interferes with PAX3-FOXO1-dependent gene regulation, resulting in potent inhibition of growth and invasive properties in FP-RMS, along with downregulation of FGF8, IL4R, MEST and PODXL expression. We additionally show that, in some FP-RMS, KDM3A also increases PAX3-FOXO1 levels. Together, our studies illuminate mechanisms of action of the KDM3A/ETS1 regulatory module, and reveal novel targetable mechanisms of PAX3-FOXO1 chromatin complex regulation, in FP-RMS.
- 24 October 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (1) , 19-29
Open AccessDependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive Rhabdomyosarcoma
Rhabdomyosarcoma (RMS), a malignancy of impaired myogenic differentiation, is the most common soft tissue pediatric cancer. PAX3-FOXO1 oncofusions drive the majority of the clinically more aggressive fusion-positive rhabdomyosarcoma (FP-RMS). Recent studies have established an epigenetic basis for PAX3-FOXO1-driven oncogenic processes. However, details of PAX3-FOXO1 epigenetic mechanisms, including interactions with, and dependence on, other chromatin and transcription factors, are incompletely understood. We previously identified a novel disease-promoting epigenetic axis in RMS, involving the histone demethylase KDM3A and the ETS1 transcription factor, and demonstrated that this epigenetic axis interfaces with PAX3-FOXO1 both phenotypically and transcriptomically, including co-regulation of biological processes and genes important to FP-RMS progression. In this study, we demonstrate that KDM3A and ETS1 colocalize with PAX3-FOXO1 to enhancers of important disease-promoting genes in FP-RMS, including FGF8, IL4R, and MEST, as well as PODXL, which we define herein as a new FP-RMS-promoting gene. We show that ETS1, which is induced by both PAX3-FOXO1 and KDM3A, exists in complex with PAX3-FOXO1, and augments PAX3-FOXO1 chromatin occupancy. We further show that the PAX3-FOXO1/ETS1 complex can be disrupted by the clinically relevant small molecule inhibitor YK-4-279. YK-4-279 displaces PAX3-FOXO1 from chromatin and interferes with PAX3-FOXO1-dependent gene regulation, resulting in potent inhibition of growth and invasive properties in FP-RMS, along with downregulation of FGF8, IL4R, MEST and PODXL expression. We additionally show that, in some FP-RMS, KDM3A also increases PAX3-FOXO1 levels. Together, our studies illuminate mechanisms of action of the KDM3A/ETS1 regulatory module, and reveal novel targetable mechanisms of PAX3-FOXO1 chromatin complex regulation, in FP-RMS.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
The androgen receptor (AR) is important in the development of both experimental and human bladder cancer. However, the role of AR in bladder cancer growth and progression is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression. To determine the mechanisms underlying these relationships, we profiled AR-expressing human bladder cancer cells by AR chromatin immunoprecipitation sequencing and complementary transcriptomic approaches in response to in vitro stimulation by the synthetic androgen R1881. In vivo functional genomics consisting of pooled shRNA or pooled open reading frame libraries was employed to evaluate 97 genes that recapitulate the direction of expression associated with androgen stimulation. Interestingly, we identified CD44, the receptor for hyaluronic acid, a potent biomarker and driver of progressive disease in multiple tumor types, as significantly associated with androgen stimulation. CRISPR-based mutagenesis of androgen response elements associated with CD44 identified a novel silencer element leading to the direct transcriptional repression of CD44 expression. In human patients with bladder cancer, tumor AR and CD44 mRNA and protein expression were inversely correlated, suggesting a clinically relevant AR–CD44 axis. Collectively, our work describes a novel mechanism partly explaining the inverse relationship between AR and bladder cancer tumor progression and suggests that AR and CD44 expression may be useful for prognostication and therapeutic selection in primary bladder cancer.Significance:This study describes novel AREs that suppress CD44 and an expected inverse correlation of AR-CD44 expression observed in human bladder tumors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
The androgen receptor (AR) is important in the development of both experimental and human bladder cancer. However, the role of AR in bladder cancer growth and progression is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression. To determine the mechanisms underlying these relationships, we profiled AR-expressing human bladder cancer cells by AR chromatin immunoprecipitation sequencing and complementary transcriptomic approaches in response to in vitro stimulation by the synthetic androgen R1881. In vivo functional genomics consisting of pooled shRNA or pooled open reading frame libraries was employed to evaluate 97 genes that recapitulate the direction of expression associated with androgen stimulation. Interestingly, we identified CD44, the receptor for hyaluronic acid, a potent biomarker and driver of progressive disease in multiple tumor types, as significantly associated with androgen stimulation. CRISPR-based mutagenesis of androgen response elements associated with CD44 identified a novel silencer element leading to the direct transcriptional repression of CD44 expression. In human patients with bladder cancer, tumor AR and CD44 mRNA and protein expression were inversely correlated, suggesting a clinically relevant AR–CD44 axis. Collectively, our work describes a novel mechanism partly explaining the inverse relationship between AR and bladder cancer tumor progression and suggests that AR and CD44 expression may be useful for prognostication and therapeutic selection in primary bladder cancer.Significance:This study describes novel AREs that suppress CD44 and an expected inverse correlation of AR-CD44 expression observed in human bladder tumors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Androgen Receptor Regulates CD44 Expression in Bladder Cancer